Czech National Bank Acquires 88,131 Shares of Pfizer Inc. $PFE

Key Points

• The Czech National Bank increased its holdings in Pfizer Inc. by 6.8%, now owning 1,389,705 shares valued at $33.7 million.
• Pfizer reported a quarterly EPS of $0.78, exceeding expectations of $0.58, along with a 10.3% year-over-year revenue increase.
• The company recently announced a $0.43 quarterly dividend, resulting in a significant annualized dividend yield of 7.2%.

Czech National Bank increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,389,705 shares of the biopharmaceutical company's stock after purchasing an additional 88,131 shares during the quarter. Czech National Bank's holdings in Pfizer were worth $33,686,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. boosted its position in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Amundi boosted its position in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new stake in Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. boosted its position in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.5%

Shares of PFE opened at $23.98 on Tuesday. The firm's 50-day moving average price is $24.76 and its 200-day moving average price is $24.25. The firm has a market capitalization of $136.34 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 0.85 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.